Magenta Therapeutics is a biotechnology company using stem cells to develop cellular therapies for immune and blood-based diseases that is headquartered in Cambridge, Massachusetts and was founded in 2016 by Jason Gardner.
Funding
Series A
On November 16, 2016 Magenta Therapeutics completed their series A funding round with $48.5 in funding from Third Rock Ventures and Atlas Ventures.
Series B
On May 2, 2017 Magenta Therapeutics completed their series B funding round with $50 million in funding from GV (lead investor), Third Rock Ventures, Partners Innovation Fund, Casidin Capital, Atlas Ventures, and Access Industries.
Series C
On April 9, 2018 Magenta Therapeutics completed their series C funding round with $52 million in funding from Casidin Capital (lead investor), The Watermill Group, Eventide Asset Management, EcoR1 Capital, Be The Match BioTherapies, and Access Industries.
Timeline
Series C funding round
On April 9, 2018 Magenta Therapeutics completed their series C funding round with $52 million in funding from Casidin Capital (lead investor), The Watermill Group, Eventide Asset Management, EcoR1 Capital, Be The Match BioTherapies, and Access Industries.
Series B funding round
On May 2, 2017 Magenta Therapeutics completed their series B funding round with $50 million in funding from GV (lead investor), Third Rock Ventures, Partners Innovation Fund, Casidin Capital, Atlas Ventures, and Access Industries.
Series A funding round
On November 16, 2016 Magenta Therapeutics completed their series A funding round with $48.5 in funding from Third Rock Ventures and Atlas Ventures.
